|
CA3115240A1
|
|
Composition for preventing or treating benign tumor
|
|
US2017369841A1
|
|
Method for modifying T cell population
|
|
BR112017012381A2
|
|
immunotherapy for angiogenic disease
|
|
US2016084841A1
|
|
Method for predicting clinical effect of immunotherapy
|
|
EP2896693A1
|
|
Antigen-specific helper t-cell receptor genes
|
|
AU2013206501A1
|
|
Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene and use of them
|
|
US2013225502A1
|
|
Combination therapy with WT1 peptide vaccine and temozolomide
|
|
AU2012227350A1
|
|
HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same
|
|
CA2846479A1
|
|
Method for measuring anti-wt1 antibody
|
|
AU2012276908A1
|
|
Receptor gene for peptide cancer antigen-specific T cell
|
|
AR076349A1
|
|
CANCER ANTIGEN AUXILIARY PEPTIDE
|
|
EP2386633A1
|
|
Novel cancer antigen eef2
|
|
CN105903006A
|
|
Cancer vaccine composition
|
|
EP2857508A2
|
|
Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
|
|
BRPI0808084A2
|
|
METHOD FOR ACTIVATION OF AUXILIARY T CELLS AND COMPOSITION FOR USE IN THE METHOD.
|
|
EP2479276A1
|
|
HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same
|
|
EP2009100A1
|
|
siRNA SPECIFIC TO WT1 17AA(-)ISOFORM AND USE THEREOF
|
|
US2010062010A1
|
|
Peptides comprising an epitope of the wilms tumor gene product
|
|
EP2186896A1
|
|
Cancer antigen peptides derived from WT1
|
|
CN101580538A
|
|
WT1-origin HLA-DR-binding antigen peptide
|
